文献速递认知障碍与痴呆

抗糖尿病药物靶点的遗传变异与阿尔茨海默病风险:一项孟德尔随机化研究

Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.
PubMed 文献 · Neurology · 2022-06-02

该研究采用两样本孟德尔随机化设计,分析4类抗糖尿病药物靶点的遗传变异与阿尔茨海默病(AD)风险的关联。血糖遗传汇总数据来自英国生物银行326,885名参与者,AD汇总数据来自既往全基因组关联研究(24,087例临床诊断AD病例和55,058名对照)。结果显示,磺脲类药物靶点的遗传变异与AD风险降低相关(每降低1 mmol/L血糖的OR=0.38,95%CI 0.19-0.72,p=0.0034);GLP-1类似物靶点也显示关联(OR=0.32,95%CI 0.13-0.79,p=0.014),但作者提醒谨慎解读。

要点

  • 磺脲类药物靶点遗传变异与AD风险降低相关(每降低1 mmol/L血糖OR=0.38,95%CI 0.19-0.72)。
  • GLP-1类似物靶点遗传变异与AD风险降低相关(OR=0.32,95%CI 0.13-0.79),但需谨慎解读。
  • 其他药物类别的结果不确定,未来需研究阐明磺脲类药物与AD的机制通路。

核心结论

  • 磺脲类药物靶点的遗传变异与AD风险降低相关,未来需研究阐明磺脲类药物与AD之间的潜在机制通路。

研究设计与样本

  • 两样本孟德尔随机化研究,分析4类抗糖尿病药物靶点的遗传变异与AD风险的关联。
  • 血糖遗传汇总数据来自英国生物银行326,885名参与者;AD汇总数据来自既往全基因组关联研究,包括24,087例临床诊断AD病例和55,058名对照。
  • 对2型糖尿病、胰岛素分泌、胰岛素抵抗和肥胖相关特征进行阳性对照分析以验证工具变量选择。

主要发现

  • 阳性对照分析中,磺脲类药物靶点的遗传变异与胰岛素分泌增高、2型糖尿病风险降低以及体重指数、腰围和臀围增加相关,与药物机制作用和既往试验证据一致。
  • 主分析中,磺脲类药物靶点的遗传变异与AD风险降低相关(每降低1 mmol/L血糖OR=0.38,95%CI 0.19-0.72,p=0.0034)。
  • 使用经证实可调节磺脲类药物靶蛋白的遗传变异rs757110进行敏感性分析,磺脲类药物结果基本不变(每降低1 mmol/L血糖OR=0.35,95%CI 0.15-0.82,p=0.016)。
  • GLP-1类似物靶点的遗传变异与AD风险降低相关(每降低1 mmol/L血糖OR=0.32,95%CI 0.13-0.79,p=0.014);但该结果应谨慎解读,因为GLP-1类似物的阳性对照分析不符合既往临床试验显示的减重效应。
  • 其他药物类别的结果不确定。

局限性

  • GLP-1类似物靶点的结果应谨慎解读,因为GLP-1类似物的阳性对照分析不符合既往临床试验显示的减重效应。
  • 其他药物类别的结果不确定。
  • 未来需研究阐明磺脲类药物与AD之间的潜在机制通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous studies have highlighted antidiabetic drugs as repurposing candidates for Alzheimer disease (AD), but the disease-modifying effects are still unclear. METHODS: A 2-sample mendelian randomization study design was applied to examine the association between genetic variation in the targets of 4 antidiabetic drug classes and AD risk. Genetic summary statistics for blood glucose were analyzed using UK Biobank data of 326,885 participants, whereas summary statistics for AD were retrieved from previous genome-wide association studies comprising 24,087 clinically diagnosed AD cases and 55,058 controls. Positive control analysis on type 2 diabetes mellitus (T2DM), insulin secretion, insulin resistance, and obesity-related traits was conducted to validate the selection of instrumental variables. RESULTS: In the positive control analysis, genetic variation in sulfonylurea targets was associated with higher insulin secretion, a lower risk of T2DM, and an increment in body mass index, waist circumference, and hip circumference, consistent with drug mechanistic actions and previous trial evidence. In the primary analysis, genetic variation in sulfonylurea targets was associated with a lower risk of AD (odds ratio [OR] = 0.38 per 1 mmol/L decrement in blood glucose, 95% CI 0.19-0.72, p = 0.0034). These results for sulfonylureas were largely unchanged in the sensitivity analysis using a genetic variant, rs757110, that has been validated to modulate the target proteins of sulfonylureas (OR = 0.35 per 1 mmol/L decrement in blood glucose, 95% CI 0.15-0.82, p = 0.016). An association between genetic variations in the glucagon-like peptide 1 (GLP-1) analogue target and a lower risk of AD was also observed (OR = 0.32 per 1 mmol/L decrement in blood glucose, 95% CI 0.13-0.79, p = 0.014). However, this result should be interpreted with caution because the positive control analyses for GLP-1 analogues did not comply with a weight-loss effect as shown in previous clinical trials. Results regarding other drug classes were inconclusive. DISCUSSION: Genetic variation in sulfonylurea targets was associated with a lower risk of AD, and future studies are warranted to clarify the underlying mechanistic pathways between sulfonylureas and AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tang B, Wang Y, Jiang X, et al. Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study. Neurology. 2022. PMID: 35654594. doi:10.1212/WNL.0000000000200771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。